Poly Pharm. stated on an interactive platform that as of the first half of 2023, it has obtained 97 patented technologies, including 80 invention patents, and 260 product approval numbers with 82 domestic chemical drug approvals and121 overseas preparation production approvals like Europe and the United States, 44 API production approval and filing numbers, 8 pharmaceutical excipient production approval and filing numbers, etc. In the first half of the year, Poly Pharm. had 67 products under review at home and abroad in the field of generic drug research and development. Currently, there are more than 150 varieties under research, involving first-time generics plus challenging patented generics, improved new drugs 505b (2), and new entity compound drugs.

From JRJ.com

September 22nd, 2023